Preview

Регионарное кровообращение и микроциркуляция

Расширенный поиск

Постишемическое невосстановление кровотока: механизмы и терапевтические мишени

https://doi.org/10.24884/1682-6655-2018-17-1-5-12

Полный текст:

Аннотация

Феномен постишемического невосстановления кровотока заключается в отсутствии полноценной перфузии миокарда на уровне микроциркуляторного русла после устранения причины, вызвавшей окклюзию коронарной артерии. Выделяют два основных механизма возникновения феномена невосстановления кровотока, возникающих у пациентов с инфарктом миокарда после первичной чрескожной ангиопластики: проявления ишемического-реперфузионного повреждения микроциркуляторного русла миокарда и эмболизация дистального артериального русла фрагментами тромба и атеросклеротической бляшки. В обзоре описаны факторы, которые способствуют появлению феномена постишемического невосстановления кровотока, механизмы его появления, принципы диагностики и терапевтические мишени.

Об авторах

М. М. Галагудза
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова» Министерства здравоохранения Российской Федерации
Россия


Д. Л. Сонин
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации
Россия


Е. И. Почкаева
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»
Россия


Список литературы

1. Кухарчик Г. А., Павлова А. М., Митрофанов Н. А. Возможности магнитно-резонансной томографии сердца при инфаркте миокарда // Вестн. Санкт-Петербург. ун-та: Медицина. - 2012. - T. 11. - № 2. - С. 73-81 [Kukharchik GA, Pavlova AM, Mitrofanov NA. Potentials of Cardiovascular Magnetic Resonance Imaging in Myocardial Infarction. Vestnik Sankt-Peterburgskogo universiteta. Meditsina. 2012;11(2):73-81. (In Russ).]

2. Сидоренко Г. И., Островский Ю. П. Феномен «невозобновления кровотока» (no-reflow) и его клиническое значение // Кардиология. - 2002. - № 5. - C. 74-80 [Sidorenko GI, Ostrovskiy YUP. Fenomen «nevozobnovleniya krovotoka» (no-reflow) i yego klinicheskoye znacheniye. Kardiologiya. 2002;5:74-80. (In Russ).]

3. Alfayoumi F, Srinivasan V, Geller M, et al. The no-reflow phenomenon: epidemiology, pathophysiology, and therapeutic approach. Rev Cardiovasc Med. 2005;6(2):72-83.

4. Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation. 2007;115(5):600-608. doi: 10.1161/CIRCULATIONAHA.106.660779

5. Bertuglia S, Giusti A. Microvascular oxygenation, oxidative stress, NO suppression and superoxide dismutase during postischemic reperfusion. Am J Physiol Heart Circ Physiol. 2003;285(3):H1064-H1071. doi: 10.1007/0-387-26206-7 4.

6. Burzotta F, Testa L, Giannico F, et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int. J. Cardiol. 2008;123(3):313-321. doi: 10.1016/j.ijcard.2006.12.018.

7. Burzotta F, Trani C, Romagnoli E et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol. 2005;46:371-376. doi: 10.1016/j.jacc.2005.04.057.

8. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol. 2006;48:2178-2185. doi: 10.1016/j.jacc.2005.12.085.

9. Chen WH, Lee PY, Ng W. et al. Safety and feasibility of the use of a distal filter protection device in percutaneous revascularization of small coronary arteries. Catheter Cardiovasc Interv. 2004;61(3):360-363. doi: 10.1002/ccd.10791.

10. Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes. Diabetes Vasc Dis Res. 2005;2:136-143. doi: 10.3132/dvdr.2005.021.

11. Czarnowska E, Karwatowska-Prokopczuk E. Ultrastructural demonstration of endothelial glycocalyx disruption in the reperfused rat heart. Involvement of oxygen free radicals. Basic Res Cardiol. 1995;90:357-364. doi: 10.1007/BF00788496.

12. Desch S, Stiermaier T, de Waha S, et al. Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset. JACC Cardiovasc Interv. 2016;9(2):113-22. doi: 10.1016/j.jcin.2015.09.010.

13. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98(7):699-710. doi: 10.1161/01. CIR.98.7.699.

14. Gao XM, Wu QZ, Kiriazis H, et al. Microvascular leakage in acute myocardial infarction: characterization by histology, biochemistry, and magnetic resonance imaging. Am J Physiol Heart Circ Physiol. 2017;312(5):H1068-H1075. doi: 10.1152/ajpheart.00073.2017.

15. Gilles S, Zahler S, Welsch U, et al. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res. 2003;60:608-616. doi: 10.1016f.cardiores.2003.08.016.

16. Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: experimental and clinical observations. Am Heart J. 2005;149(4):580-584. doi: 10.1016/j.ahj.2004.12.009.

17. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the noreflow phenomenon during coronary occlusion-reperfusion. Circulation. 1987;75:292-298. doi: 10.1161/01.CIR.75.1.292.

18. Golino P, Ragni M, Cirillo P et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med. 1996;2(1):35-40. doi: 10.1038/nm0196-35.

19. Hale SL, Dae M, Kloner RA. Hypothermia during reperfusion limits "no-reflow" injury in a rabbit model of acute myocardial infarction. Cardiovasc Res. 2003;59(3):715-722. doi: 10.1016/S0008-6363(03)00456-5.

20. Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J Cardiovas Pharmacol Therap. 2008;13(3):226-232. doi: 10.1177/1074248408320278.

21. Han JY, Horie Y, Fan JY, et al. Potential of 3,4-dihydroxy-phenyl lactic acid for ameliorating ischemia-reperfusion-induced microvascular disturbance in rat mesentery. Am J Physiol Gastrointest Liver Physiol. 2009;296(1):G36-44. doi: 10.1152/ajpgi.90284.2008.

22. Harris NR, Rumbaut RE. Age-related responses of the microcirculation to ischemia-reperfusion and inflammation. Pathophysiology. 2001;1:1-10. doi: 10.1016/s0928-4680(01)00064-5.

23. Hayat SA, Senior R. Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur Heart J. 2008;29:299-314. doi: 10.1093/eurheartj/ehm621.

24. Hervas A, de Dios E, Forteza MJ, Mwana G, Nuсez J et al. Intracoronary Infusion of Thioflavin-S to Study Microvascular Obstruction in a Model of Myocardial Infarction. Rev Esp Cardiol (Engl Ed). 2015;68(11):928-34. doi: 10.1016/j. rec.2015.04.016.

25. Heusch G. The Coronary Circulation as a Target of Cardioprotection. Circ Res. 2016;118(10):1643-58. doi: 10.1161/CIRCRESAHA.116.308640.

26. Higginson LA, White F, Heggtveit HA, et al. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation. 1982;65:62-69. doi: 10.1161/01.CIR.65.1.62.

27. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7. doi: 10.1016/S0735-1097(02)02626-8.

28. Iwakura K, Ito H, Kawano S et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol. 2001;38:472-477. doi: 10.1016/S0735-1097(01)01405-X.

29. Kereiakes DJ, Turco MA, Breall J et al. A novel filter-based distal embolic protection device for percutaneous in tervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008;1(3):248-257. doi: 10.1016/j.jcin.2008.03.009.

30. Kleinbongard P, Bose D, Baars T et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res. 2011;108(3):344-352. doi: 10.1161/CIRCRESAHA.110.235713.

31. Kloner R. A. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharm Ther. 2011;16(3-4):244-250. doi: 10.1177/1074248411405990.

32. Kloner R. A. No-reflow: Basic science to clinical phenomenon. Basic Res Cardiol. 2006;101(9):357-358. doi: 10.1136/heart.87.2.162.

33. Kloner RA, Ganote CE, Jennings RB. The «no-reflow» phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508. doi: 10.1172/JCI107898.

34. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation. 1980;62:945-952. doi: 10.1161/01.CIR.62.5.945.

35. Limbruno U, De Carlo M, Pistolesi S, et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J. 2005;150:102-108. doi: 10.1016/j.ahj.2005.01.016.

36. McLaughlin MG, Stone GW, Aymong E, et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J Am Coll Cardiol. 2004;44:1215-1223. doi: 10.1016/j.jacc.2004.06.053.

37. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007;357:1631-1638. doi: 10.1056/NEJMra065985.

38. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383-9. doi: 10.1016/j.jacc.2009.12.054.

39. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54(4):281-292. doi: 10.1016/j.jacc.2009.03.054.

40. Niccoli G, Giubilato S, Russo E et al. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J. 2008;29:1843-1850. doi: 10.1093/eurheartj/ehn325.

41. Niccoli G, Lanza G A, Shaw S et al. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur. Heart J. 2006;27:1793-1798. doi: 10.1093/eurheartj/ehl119.

42. Niccoli G, Marino M, Spaziani C et al. Prevention and treatment of no-reflow. Acute Card Care. 2010;12(3):81-91. doi: 10.3109/17482941.2010.498919.

43. Pochkaeva EI, Sonin DL, Larionov AA et al. Fluorescent indocyanine green imaging enables in vivo and ex vivo quantification of myocardial infarct size. [abstract] European Heart Journal. 2016;37(1):50.

44. Porto I, Selvanayagam JB, Van Gaal WJ et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation. 2006;114(7):662-669. doi: 10.1161/CIRCULATIONAHA.105.593210.

45. Przyklenk K, Kloner RA. Reperfusion injury by oxygen-free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res. 1989;64(1):86-96. doi: 10.1161/01.RES.641.86.

46. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no-reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. 2002;283(3):H1099-H1107. doi: 10.1152/ajpheart.00270.2002.

47. Reffelmann T, Kloner RA. The «no-reflow» phenomenon: basic science and clinical correlates. Heart. 2002;87(2):162- 168. doi: 10.1136/heart.87.2162.

48. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol. 2006;101:359-372. doi: 10.1007/s00395-006-0615-2.

49. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72:950- 957. doi: 10.1002/ccd.21715.

50. Rezkalla SH, Stankowski RV, Hanna J et al. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv. 2017;10(3):215-223. doi: 10.1016/j.jcin.2016.11.059.

51. Bolognese Sorajja P, Gersh BJ, Costantini C et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 2005;26:667-674. doi: 10.1093/eurheartj/ehi167.

52. Stone GW, Martin JL, de Boer MJ et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv, 2009;2(5):366-375. doi: 10.1161/CIRCINTERVENTIONS.108.840066.

53. Stone GW, Maehara A, Witzenbichler B et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. INFUSE-AMI Investigators. JAMA. 2012;307(17):1817-26. doi: 10.1001/jama.2012.421.

54. Svilaas T, Vlaar PJ, van der Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008,358:557-567. doi: 10.1056/NEJMoa0706416.

55. Takahashi T, Hiasa Y, Ohara Y et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol. 2007,100:35-40. doi: 10.1016/j.amjcard.2007.02.049.

56. The TIMI Study Group. The Thrombolysis In Myocardial Infarction [TIMI] trial. Phase I findings. N Engl J Med. 1985,312:932-936. doi: 10.1056/NEJM198504043121437.

57. Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primarypercutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642.

58. Thiele H, de Waha S, Zeymer U et al. Effect of aspiration thrombectomy on microvascular obstruction in NSTEMI patients: the TATORT-NSTEMI trial. J Am Coll Cardiol. 2014;64(11):1117-24. doi: 10.1016/j.jacc.2014.05.064.

59. Turschner O, D'Hooge J, Dommke C et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J. 2004; 25:794-803. doi: 10.1016/j.ehj.2004.01.006.

60. Valent P, Sillaber C, Baghestanian M et al. What have mast cells to do with edema formation, the consecutive repair and fibrinolysis? Int Arch Allergy Immunol. 1998;115(1):2-8. doi: 10.1159/000023823.

61. Van Gaal WJ, Banning AP. Percutaneous coronary intervention and the no-reflow phenomenon. Expert Rev Cardiovasc Ther. 2007;5(4):715-731. doi: 10.1586/14779072.5.4.715.

62. Van't Hof AW, Liem A, Suryapranata H et al. Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998,97:2302-2306. doi: 10.1161/01.CIR.97.23.2302.

63. Van Kranenburg M, Magro M, Thiele H et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging. 2014;7(9):930-9. doi: 10.1016/j.jcmg.2014.05.010.

64. Vignali L, Talanas G, Saia F et al. Genetic association between the 1976T_C polymorphism in the adenosineA2 receptor and angiographic no-reflow phenomenon. [abstract] Il Giornale italiano di Cardiologia Invasiva, 2007;3(1):109.

65. Vlaar PJ, Svilaas T, van der Horst IC et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915-1920. doi: 10.1016/S0140-6736(08)60833-8.

66. Wong DT, Leung MC, Richardson JD et al. Cardiac magnetic resonance derived late microvascular obstruction assessment post ST-segment elevation myocardial infarction is the best predictor of left ventricular function: a comparison of angiographic and cardiac magnetic resonance derived measurements. Int J Cardiovasc Imaging. 2012;28(8):1971-81. doi: 10.1007/s10554-012-0021-9.

67. Wu KC. CMR of microvascular obstruction and hemorrhage in myocardial infarction. J Cardiovasc Magn Reson. 2012;14:68. doi: 10.1186/1532-429X-14-68.

68. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest. 2002;122:1322-1332. doi: 10.1378/chest.122.4J322.

69. Zaman AK, French CJ, Spees JL et al. Vascular rhexis in mice subjected to non-sustained myocardial ischemia and its therapeutic implications. Exp Biol Med (Maywood). 2011;236(5):598-603. doi: 10.1258/ebm.2011.011026.


Для цитирования:


Галагудза М.М., Сонин Д.Л., Почкаева Е.И. Постишемическое невосстановление кровотока: механизмы и терапевтические мишени. Регионарное кровообращение и микроциркуляция. 2018;17(1):5-12. https://doi.org/10.24884/1682-6655-2018-17-1-5-12

For citation:


Galagudza M.M., Sonin D.L., Pochkaeva E.I. The no-reflow phenomenon: mechanisms and therapeutic targets. Regional blood circulation and microcirculation. 2018;17(1):5-12. (In Russ.) https://doi.org/10.24884/1682-6655-2018-17-1-5-12

Просмотров: 195


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-6655 (Print)